ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease
...ormation [1].
Phase I studies demonstrated good tolerability of EHT 0202 in both young
and aged healthy volunteers; importantly, no sedation or
emesis were observed
clinically.
Preclinical studies have shown that EHT 0202 protects cortical neurons
against Abeta42-induced stress and that this n...
Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
...Victory is pleased with the results to date and is
confident that MGX006 will provide an important therapeutic alternative for
patients suffering from
emesis of various etiologies," continued Dr.
Scranton.
"MGX006 represents a key milestone for Victory," stated Matthew Heck,
President and CEO. "This novel...
GlaxoSmithKline Announces New Drug Application and Phase III Results for Rezonic(TM)/Zunrisa(TM) (Casopitant)
...y. Cancer.
2004;100,10 :2261-2268.
(7) Hesketh PJ, et Al. Differential involvement of neurotransmitters
through the time course of cisplatin-induced
emesis as revealed by therapy
with specific receptor antagonists. Eur J Cancer. 2003; 39:1074-1080.
(8) Kris M. et. Al. Consensus proposals for the prevent...
Bema Fentanyl Demonstrates Substantial Transmucosal Delivery In
Absolute Bioavailability Study
...R) nanocochleate technology on Bioral Amphotericin
B targeting fungal infections and considering products targeted at
other acute conditions including
emesis and insomnia in the
BEMA(TM) technology. The company's headquarters are located in
Morrisville, North Carolina and its principal laboratory is located...
Palatin Technologies and King Pharmaceuticals Report Data Showing
Improvements in Sexual Relationship and Self-Esteem in Patients
with Erectile Dysfunction Treated with Bremelanotide
...verse
events leading to patient discontinuation from the study were
nausea,
emesis and blood pressure increase.
emesis and blood
pressure increase were protocol-mandated reasons for patient
disc...
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American
Society of Clinical Oncology (ASCO) Annual Meeting
...5 mg, oral
dexamethasone 20 mg and aprepitant 285 mg prior to their first
cycle of chemotherapy. Endpoints of the study included complete
response (no
emesis or rescue medication), no emesis, and no
significant nausea (Visual Analogue Score (VAS; 0-100) less than
25) on Day 1, during the delayed period of D...
MGI Pharma Summarizes Data Presented at the 2007 American Society
of Clinical Oncology (ASCO) Annual Meeting
...ycle of chemotherapy. Endpoints of the study included complete
response (no
emesis or rescue medication), no emesis, and no
significant nausea (Visual Analogu... during the
overall period of Days 1-5.
On Day 1, 100% of patients had no
emesis and at least 95% of
patients had no emetic episodes in the delayed and over...
Emesis
Vomiting (known medically as
emesis and informally as throwing up and a number ... Fecal vomiting is a kind of
emesis in which half-digested matter is expelled ... An
emesis basin is a shallow basin with a kidney-shaped footprint and sloping walls . Various sizes of
emesis basin a...
Vomiting
...ith diarrhea) ... vomiting Forcible ejection of contents of stomach through the mouth. Called also emesis. ... Vomiting (known medically as
emesis and informally as throwing up ... Vom·it·ing n. The spasmodic ejection of matter from the stomach through the mouth. ... Vomiting may be prec...
Nausea and vomiting
...auses of nausea and vomiting . ... can cause nausea and vomiting , as can general ... Nausea and Vomiting Key Terms: Antiemetics ,
emesis , Retching. ... The mechanisms that control nausea and vomiting are not fully understood, but ... More about Nausea and Vomiting : Caus...